These TCSP-based biomarkers predicted response to anti-PD-1 therapies in HNSCC, NSCLC, and Melanoma, and out-performed the on label PD-L1 test and Tumor Mutational Burden (TMB). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.